Loncar Cancer Immunotherapy ETF (CNCR) Surpasses $50 Million in Assets Under ManagementBusiness Wire (press release)Launched with a modest seed investment of $2.5 million on Oct. 13, 2015, the ETF has been offering exposure to public companies at the f… Continue reading
Harvard Health (blog) |
Stem–cell transplant: A possible high-risk/high-reward treatment for scleroderma
Harvard Health (blog) Some medical news stories don’t get the attention they deserve. Perhaps it’s because the disease is rare and not many people have ever heard of it. I think this story about a new treatment for scleroderma is a good example. What’s scleroderma? The term … |
BioPharma-Reporter.com |
Lonza rejigs network to tap ‘huge potential’ of cell and gene therapies
BioPharma-Reporter.com The establishment of what Lonza calls ‘Centers of Excellence for Cell and Gene Therapy‘ comes after a wave of R&D and investment in the sector by the Swiss contract manufacturing organization (CMO). “The landscape of modern medicines is constantly … |
Capital Press |
CRISPR: The latest word in genetics
Capital Press It took about a decade to realize that the CRISPR sequence — an acronym for Clustered Regularly Interspaced Palindromic Repeats — acted as the bacteria’s immune system. The microbe had genes that normally belong to viruses in a specific location at … |